Recent Updates
Recently added Catalysts
ATHE Positive Sentiment Score: 65/100

Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 15/3/2023 The Proposed issue is: A placement or other type of issue

Key Takeaway: Alterity Therapeutics Limited has announced a proposed issue of 23,479,200 ordinary fully paid securities for cash consideration at AUD 0.00760 per security. The issuance is intended to be quoted on the ASX and does not require any external approvals. This capital raise could support the company's future projects or operations, leveraging the equity market under existing terms.

Market Sentiment Analysis

POSITIVE FACTORS

  • Proposed issuance of 23,479,200 ordinary fully paid securities indicates potential for capital raise.
  • Placement aims to provide cash consideration for future projects or operations.
  • No external approvals needed, streamlining the process for the proposed issue.

Full Press Release Details

THERAPEUTICS LIMITED
of this announcement
number of +securities proposed to be issued for a placement or other type of issue
ASX +security code +Security description Maximum Number of +securities to be issued
ATH ORDINARY FULLY PAID 23,479,200
Refer to next page for full details of the announcement
THERAPEUTICS LIMITED
(the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of
the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing
the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation
of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing
Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance
with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for
1.2 Registered Number Type Registration Number
ABN 37080699065
1.4 The announcement is
New announcement
1.6 The Proposed issue is:
A placement or other type of issue
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?
No
Is the proposed security a New class' (+securities in a class that is not yet quoted or recorded by ASX) or an Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Will the proposed issue of this +security include an offer of attaching +securities?
Existing class NO
of +securities proposed to be issued
+security code and description
: ORDINARY FULLY PAID
of +securities proposed to be issued
the +securities proposed to be issued being issued for a cash consideration?
In what currency is the cash consideration being paid? What is the issue price per +security?
AUD - Australian Dollar AUD 0.00760
these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
to the costs and timing benefits of completing the placement.
7E.1 Will there be a lead manager or broker to the proposed issue?
7E.2 Is the proposed issue to be underwritten?
of any other material fees or costs to be incurred by the entity in connection with the proposed issue
7F.01 The purpose(s) for which the entity is issuing the securities
Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?
other information the entity wishes to provide about the proposed issue

Frequently Asked Questions

How many securities will Therapeutics Limited issue?

Therapeutics Limited plans to issue a maximum of 23,479,200 ordinary fully paid securities.

What is the issue price per security?

The issue price for each security is AUD 0.00760.

Do external approvals need to be obtained for the issue?

No external approvals are required before proceeding with the issue.

Will the securities have equal ranking with existing ones?

Yes, the new securities will rank equally in all respects with existing issued securities.

Is the proposed issue underwritten or managed by a broker?

The announcement does not specify if the issue will be underwritten or managed by a broker.

Last updated: Mar 15, 2023